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Abstract: The Ubiquitin-Proteasomes System (UPS) and autophagy, two main intracellular protein degra-
dation pathways within the eukaryotic cells which were originally regarded as rather independent, seem 
to be very closely related. Proteasome inhibitors, including the multipathway inhibitor bortezomib, are 
drawing increased attention for their therapeutic potential in the treatment of chronic inflammation and 
cancer, especially tumours with a high degree of malignancy. The over-activation of autophagy induces 
cell death and may act as a powerful tumour-suppressing mechanism. However, autophagy, serving as 
an important mechanism to generate nutrients in time of cellular stresses, may directly contribute to the 
survival of cells treated with proteasome inhibitors, and in consequence, may decrease the effectiveness 
of therapy. Results of studies performed on several cancer cell lines demonstrated synergy between pro-
teasome inhibitors and autophagy inhibitors. Those results became the base for ongoing clinical trials 
investigating autophagy inhibition in combination with anti-cancer therapies, including bortezomib. 
This review provides summary of the latest data on the functioning of the UPS and the mechanisms of 
autophagy. The new insights describing the main pathways of autophagy activation in response to UPS 
inhibition related to: (i) Unfolded Protein Response, (ii) PI3K/Akt/mTOR pathway, and (iii) formation 
of aggresomes, are discussed. It is concluded that concomitant inhibition of the two main cellular protein 
degradation systems may provide new therapeutic modalities for cancer treatment. (Folia Histochemica 
et Cytobiologica 2013, Vol. 51, No. 4, 249–264)
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Abbreviations
4E-BP1 — eukaryotic initiation factor 4E-binding 
protein 1; ALLN — Acetyl leucyl-leucyl-norleucinal 
(also known as N-acetyl-leucyl-leucyl-norleucinal); 
AMPKa1 — AMP-activated protein kinase a1 subunit; 
ATF4 — Activating Transcription Factor 4; ATF6 — 
activating transcription factor 6; Atg — autophagy-re-
lated proteins; BAG3 — Bcl-2 associated athanogene 3; 
CRLs — cullin-containing RING-finger ligases; eIF2a 
— eukaryotic initiation factor 2; ERK1/2 — extracellu-
lar signal-regulated kinase 1 and 2; HDAC6 — tubulin 
deacetylase histone deacetylase 6; HECT — homolo-
gous to E6-associated protein carboxy terminus; HIF — 
hypoxia inducible factor; HIF-1a — hypoxia-inducible 
factor-1a; HSF1 — heat-shock factor 1; HSP70 — heat 
shock protein70; HSP90 — heat shock protein90; IRE1 
— inositol-requiring kinase 1; JNK — c-Jun NH2-ter-
minal kinase; LC3 — microtubule-associated protein 
light chain 3; LC3-I (LC3A) — C-terminally cleaved 
LC3; LC3-II (LC3B) — phosphatidylethanolamine — 
conjugated form of LC3-I; MAPK — mitogen-activated 
protein kinase; MEFs — murine embryonic fibroblasts; 
MEK1/2 — MAPK kinase 1 and 2; mTOR — mamma-
lian target of rapamycin; mTORC1 — mTOR complex 
1; mTORC2 — mTOR complex 2; NBR1 — neighbour 
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of BRCA1 gene 1 protein; p70S6K — p70S6 kinase; 
PDK1 — 3-phosphoinositide-dependent protein ki-
nase-1; PERK — ER-resident protein kinase; PGPH 
activity — peptidyl-glutamyl peptide-hydrolysing-like 
activity; PI3K III — phosphatidyl inositol 3-phosphate 
kinase class III; RING — really interesting new gene; 
SESN2 — sestrin-2; TSC2 — tuberous sclerosis2; 
Ulk1/2 — Unc51-like Ser/Thr kinases 1 and 2; UPR 
— unfolded protein response; UPS — Ubiquitin-Pro-
teasomes System; UVRAG — ultraviolet irradiation 
resistance-associated gene; VHL — von Hippel-Lindau 
tumour suppressor protein
Within the eukaryotic cell there are two main 
intracellular protein degradation pathways: the 
Ubiquitin-Proteasomes System (UPS) and autopha-
gy. Intracellular protein degradation processes have 
gained researcher’s attention quite recently, since 
it has been shown that they play pivotal roles in the 
regulation of many cellular activities, including the 
cell cycle, cell differentiation and apoptosis. Mo-
reover, clinical data suggested the existence of close 
relationships indicating a close connection between 
UPS, autophagy and pathogenesis of many diseases. 
Both UPS and autophagy are involved in modification 
of the course of inflammatory processes, and they 
are also considered to be important factors which 
can facilitate cancer treatment. The malfunction in 
clearance of misfolded or aggregated proteins from 
the cytoplasm of nerve and glial cells seems to be 
an especially common pathogenic event in a variety 
of neurodegenerative disorders. Despite increasing 
knowledge about both the UPS and autophagy, and 
the effects caused by their inhibition, information on 
the interactions of these two systems is still fragmen-
ted. The subject of this review article is a summary 
of the latest information on (1) the functioning of 
the UPS, (2) the mechanisms of autophagy and (3) 
pathways of autophagy activation in response to the 
UPS inhibition.
Proteasomal degradation pathway
Commonly found in eukaryotic cells, the Ubiquitin
-Proteasomes System (UPS) is responsible for the 
degradation of redundant or abnormal (e.g. unfolded 
or misfolded) short-lived proteins [1]. The protein 
degradation performed through UPS is a multistage 
process which occurs in the presence of ubiquitin, 
three classes of enzymes and proteasome. 
In the initial stage the protein substrate to be de-
graded binds to ubiquitin. Ubiquitin is a short 76-ami-
no acid long, highly conserved protein (ubiquitin in 
humans and yeast differs by only three amino acid resi-
dues). The attachment of single molecule of ubiquitin 
to a substrate’s lysine to form an isopeptide bond, 
results in substrate monoubiquitination. Protein subs-
trates can be also ubiquitinated on numerous lysines, 
resulting in their multiubiquitination [2]. In addition, 
lysines on the substrate-conjugated ubiquitin may be 
utilized, to catalyse further cycles of ubiquitination, 
resulting in substrate’s polyubiquitination [2, 3]. Al-
though ubiquitin molecule contains seven lysines, it 
is known that the attachment of a polyubiquitin chain 
to a target protein is mediated only by ubiquitin lysi-
ne residue 48, leading to the degradation of a target 
protein [4]. Monoubiquitination, multiubiquitination 
and polyubiquitination moderated by ubiquitin’s 
lysine residues other than residue 48 usually results 
in regulatory functions (e.g. in: protein transport be-
tween the nucleus and cytoplasm, DNA repair and 
gene expression, kinase activation, DNA damage 
tolerance, signal transduction and endocytosis) [3, 5]. 
The molecular mechanisms of enzymatic degra-
dation by UPS has been thoroughly describe [1, 3, 4, 
6–11]. In short successive action of three enzymes, 
symbolically called E1, E2, and E3, is necessary to 
the proper polyubiquitination of the substrate being 
degraded. The first step (Figure 1.1) of the degrada-
tion process mediated by UPS is an establishment 
of a strong bond between glycine at the C-terminus 
of ubiquitin and the cysteine of the active site of the 
enzyme E1 (ubiquitin activating enzyme). To esta-
blish this connection, energy from ATP hydrolysis is 
required. Then (Figure 1.2), as an activated ubiquitin 
is transferred to the E2 enzyme (ubiquitin-conjugating 
enzyme), complex E2 enzyme-activated ubiquitin in-
teracts with the specific enzyme E3 (ubiquitin ligase) 
to transfer ubiquitin into the specific substrate (Figure 
1.3). In contrast to a presence of a single E1 enzyme 
in eukaryotic cells multiple E2 and E3 enzymes form 
pairs to provide the specificity required to regulate 
selective protein degradation [7]. The E3, which may 
be a multi-protein complex, is, in general, responsible 
for targeting ubiquitination to specific substrate pro-
teins. Because of the great number of distinct protein 
classes and individual proteins whose proteasomal 
degradation must be securely controlled, the number 
of existing E3 ubiquitin ligases has to be high, and, 
indeed the number of known E3 enzymes exceeds 
one thousand [5, 7, 11]. The classification of ubiquitin 
ligases is based on their biochemical and structural 
features. The best known subclasses include: HECT 
(homologous to E6-associated protein carboxy ter-
minus), RING-fingers (RING, really interesting new 
gene) and U-box domains (a modified RING motif 
without the full complement of Zn2+-binding ligands). 
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Within subclass of RING-fingers ubiquitin ligases two 
main subfamilies can be distinguished: (i) cullin-con-
taining RING-finger ligases (CRLs) and (ii) those in 
which the RING-finger and substrate binding domains 
are contained on the same polypeptide [7, 12–14]. 
Whereas E3 enzymes belonging to the HECT subclass 
have a direct catalytic role during ubiquitination, the 
E3 enzymes from subclasses RING and U-box facilita-
te protein ubiquitination. E3 substrates are recognized 
by the specific ubiquitin ligases (E3 enzymes) based 
on their various structural determinants including pri-
mary sequence (binding determinant for e.g. MDM2 
ubiquitin ligase), post-translational modification, 
such as phosphorylation (binding determinant for 
e.g. bTrCP ubiquitin ligase), oxidation, or presence 
of N-linked high-mannose oligosaccharides (binding 
determinant for e.g. Fbx2 ubiquitin ligase), and pro-
tein folding state (binding determinant for e.g. CHIP 
ubiquitin ligase) [7, 12–14]. Another very important 
substrate recognition method by E3 enzymes is an 
oxygen-sensing mechanism mediated by the action 
of the von Hippel-Lindau tumour suppressor protein 
(VHL), E3 ubiquitin ligase of hypoxia inducible factor 
[15, 16]. Properly recognized substrates subsequently 
undergo numerous rounds of ubiquitination which re-
sults in poliubiquitinated proteins that can be further 
process by the proteasome (Figure 1.4). 
The final, third stage, is dependent on the pro-
teasome. The proteasome is a proteolytic complex 
present in both the nucleus and the cytosol. It 
is composed of three subunits: the main part — 
a hollow cylindrical multi enzymatic core (20S-unit), 
responsible for the degradation of the compounds [8, 
17] — and two additional 19S-unit regulatory caps, 
sharing the same structure and located at the opposite 
ends of the 20S-unit (Figure 1.4). The 19S-units are 
composed of two sub-complexes. The external one 
is the lid, which is believed to be responsible for the 
identification of polyubiquitinated compounds assi-
gned for proteasome-mediated degradation and for 
the removal of ubiquitin tag. The internal sub-com-
plex of 19S-unite, the base, seems to be responsible 
for denaturation of the substrate via the action of six 
ATPase subunits. During the last stage of degradation 
the protein tagged with a polyubiquitinated chain is 
recognized by the 19S proteasome subunit, then the 
19S-unit binds and cleaves the polyubiquitin chain of 
the target protein, thereby directing it into the 20S 
Figure 1. Schematic diagram of the Ubiquitin-Proteasome System. The first step (Figure 1.1) of the degradation process is an 
establishment of a strong bond between ubiquitin and enzyme E1 (ubiquitin activating enzyme) which requires energy from 
ATP hydrolysis is required. Then (Figure 1.2), as an activated ubiquitin is transferred to the E2 enzyme (ubiquitin-conjugating 
enzyme), complex E2 enzyme-activated ubiquitin interacts with the specific enzyme E3 (ubiquitin ligase) to transfer ubiquitin on 
the specific substrate (Figure 1.3). Properly recognized substrates subsequently undergo numerous rounds of ubiquitination which 
results in poliubiquitinated proteins that can be further processed by the proteasome (Figure 1.4). The proteasome is composed 
of three subunits: the main part multi-enzymatic core (20S-unit), responsible for the degradation of the compounds, and two 
additional 19S-unit regulatory caps. The 20S-unit multi catalytic core is composed of four rings: two identical non-catalytic alpha 
subunit (a1-a7) rings and two identical catalytic beta subunits (b1-b7) rings, forming a special abba arrangement. Detailed 
description of the processes has been provided in the main text
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catalytic core [9, 17]. Finally, protein is degraded by 
the 20S proteasome subunit endopeptidases to short 
10-12-amino-acid segments. The 20S-unit multi ca-
talytic core is composed of four rings: two identical 
non-catalytic alpha subunit (a1-a7) rings and two 
identical catalytic beta subunit (b1-b7) rings, forming 
a special abba arrangement. The catalytic cleavage of 
peptides is facilitated by three proteolytically active 
beta subunits, b1 (caspase-like or peptidyl-glutamyl 
peptide-hydrolysing-like (PGPH) activity), b2 (trypsin
-like activity) and b5 (chymotrypsin-like activity). The 
b1 subunit cleaves the peptide bonds at acidic residu-
es, the b2 subunit mainly cleaves peptides past basic 
amino acids and the b5 subunit hydrolyses peptide 
bonds at hydrophobic residues. In all of the three 
b-subunits an N-terminal threonine residue (Thr1) is 
considered to be the catalytically active amino acid [8].
Proteasome inhibitors
The proper function of the UPS allows degradation 
not only of structural and constitutive proteins, but 
also of many regulatory proteins, including those 
which control biosynthetic pathways and cell cycle 
as well as transcription factors, proteins encoded by 
oncogenes and immune response proteins. It was, 
therefore, the matter of time to design and synthesize 
different groups of chemicals for proteasome inhi-
bition with a potential use in the treatment of cancer 
and autoimmune and inflammatory diseases. 
The first reported proteasome inhibitors were 
acetyl leucyl-leucyl-norleucinal (also known as ALLN 
or N-acetyl-leucyl-leucyl-norleucinal) and leupeptin 
[18]. A wide variety of both natural and synthetic sub-
stances, which inhibit the activity of the proteasome by 
reversible or irreversible binding to the active site of 
its 20S catalytic subunit has been discovered (Table 1). 
Proteasome inhibitors are divided in specific 
classes according to their chemical structure and me-
chanism of inhibition. Covalent inhibitors are mainly 
electrophilic and react with the catalytic γ-hydroxyl of 
Thr1 in the active sites. In result, they either reversibly 
(majority of peptide aldehydes, peptide boronates, 
polyphenols and terpenoids) or irreversibly (majority 
of epoxyketones, peptide vinyl derivatives, b-Lacto-
nes and derivatives) inhibit the proteasome [19–21]. 
It should be emphasized that many of well-known 
natural proteasome inhibitors, such as epoxomicin, 
lactacystin and syringolin A belong to covalent in-
hibitors. The lack of reactive group in non-covalent 
inhibitors is often associated with poor specificity and 
instability [22]. Their interaction with the proteasome 
active sites occurs via weak bonds (hydrophobic, elec-
trostatic, hydrogen and/or van der Waals) [19]. The 
actions of proteasome inhibitors are multidirectional 
including control of cell cycle, regulation of pro- and 
anti-apoptotic proteins, sensitization to ligand-in-
duced apoptosis, activation of bone morphogenetic 
protein signalling, and global translational repression 
(for review see [21]). 
Most of known proteasome inhibitors have low 
specificity, poor metabolic stability and associate with 
the proteasome in an irreversible way, which limits their 
therapeutic use. Peptide boronates are considered as the 
most promising class of proteasome inhibitors for clinical 
use. The compounds of this class have 1000 times greater 
potency than the analogues of peptide aldehydes and are 
highly specific in relation to proteasome. Peptide boro-
nates reversibly inhibit the chymotrypsin-like activity, 
and dissociate slowly, thus providing a stable inhibition 
of proteasomal activity [19, 20, 23, 24]. Of special clinical 
significance was the introduction into the cancer treat-
ment the dipeptide boronic acid, bortezomib (PS-341), 
which reversibly and selectively inhibits the proteasome 
[19, 21, 25, 26]. Lately, two other inhibitors delanzomib 
and ixazomib have been approved for phase II and III, 
respectively, of clinical trials [27]. 
Recently, Qureshi et al. have demonstrated that 
two compounds present in grapes, blueberries and 
red wine — resveratrol and pterostilbene — acted 
as proteasome inhibitors (Table 1), successfully 
inhibiting all proteasomal enzymatic activities, i.e. 
caspase-, trypsin-, and chymotrypsin-like [28]. Those 
compounds, naturally occurring polyphenols, have 
been intensively studied because of their pleiotropic 
health benefits, including anti-inflammatory, anti-aging, 
antioxidant, cardioprotective, and neuroprotective ac-
tivities [29, 30]. Due to these properties and their wide 
distribution throughout the plant kingdom, resveratrol 
and pterostilbene are considered as potential preventi-
ve/therapeutic agents also against cancer. The knowled-
ge about the potential of resveratrol and pterostilbene 
to inhibit proteasome activity compels to re-evaluate the 
previously obtained results observed after resveratrol 
and pterostilbene administration [31–34].
Interestingly, current studies have revealed new 
aspects of proteasome function in cells, including 
the process of autophagy and therapeutic usage of 
proteasome inhibitors in co-treatment in cancer. Ho-
wever, it should be emphasized, that interference in 
such complex systems as UPS may lead not only to the 
expected therapeutic effects, but also to unexpected 
adverse side effects. 
Autophagy
Autophagy is a ubiquitous and evolutionarily highly 
conserved process for degrading misfolded proteins, 
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Table 1. Characterisation of proteasome inhibitors commonly used in experimental and clinical studies
Name ChT
-like 
activity
T-like 
activity
C-like 
activity
Type  
of inhibition
Stage of development 
COVALENT INHIBITORS
Peptide aldehydes
ALLN (Ac-Leu-Leu-Nle-al.; Calpain Inhibitor I) +  – + Reversible 
ALLM (Ac-Leu-Leu-Met-al.; Calpain Inhibitor II) +  – + Reversible
MG132 (Z-Leu-Leu-Leu-al) +  – + Reversible
MG115 (Z-Leu-Leu-Nva-al) +  – + Reversible
Z-Leu-Leu-Phe-H +  –  – Reversible
Z-Ile-Glu(OtBu)-Ala-Leu-H (PSI) +  – + Reversible 
Peptide boronates
MG262 (Z-Leu-Leu-Leu-B(OH)2 +  – + Reversible
Bortezomib (PS-341) + – (+) Reversible FDA-approved (Velacade)
Delanzomib (CEP-18770) + – – Reversible Phase I II
Ixazomib (MLN-2238, MLN-9708) + – – Reversible Phase III
Epoxyketones
Epoxomicin + (+) (+) Irreversible
Carfilzomib (PR-171) + – – Irreversible FDA-approved (Kyprolis)
Oprozomib (ONX-0912/PR-047) + – – Reversible Phase I II
B-lactones and derivatives
Lactacystin + +  – Irreversible
Clasto-Lactacystin beta-lactone + +  – Irreversible
Marizomib (NPI-0052, Salinosporamide A) + + (+) Irreversible Phase Ib
Polyphenols
(-)-Epigallocatechin gallate (EGCG) +  –  – Reversible 
Resveratrol + + +
Pterostilbene + + +
Terpenoids
Pristimerin +  –  – Reversible
Celastrol +  –  – Reversible 
Peptide vinyl derivatives — Syrbactins
Syringolin A + + + Irreversible
NON-COVALENT INHIBITORS
TMC-95 and derivatives – – –
TMC-95A + + + Reversible 
Peptides and Pseudopeptides — Natural peptides
Argyrin A + + + Reversible 
Gliotoxin +  –  – Reversible 
Non peptide molecules with no electrophilic function
Aclacinomycin A (Aclarubicin) +  –  – Reversible 
Bisbibenzyl derivatives 
Marchantin M + – + Reversible
Inhibits ChT-like — chymotrypsin-like; T-like — trypsin-like; C-like — caspase-like activity
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long-lived proteins, macromolecules and damaged 
or old organelles by encircling them with membrane 
with a following fusion of the vesicle with lysosomes. 
In mammalian cells three main types of autophagy 
have been described (for review see [35, 36]). Microau-
tophagy is a process in which lysosomes directly take 
up portions of cytoplasm for degradation, whereas in 
chaperone-mediated autophagy cytoplasmic chaperone 
proteins recognize and transport soluble proteins to 
the lysosomes. Macroautophagy (referred here as au-
tophagy, a focus of this review), is a process in which 
a non-selective sequestration of cytoplasmic material, 
including organelles, is followed by digestion in lysoso-
mes. Autophagy is considered as a protection process 
which enables cells to survive adverse conditions like 
starvation, infections, toxins and other types of cell 
stress. Autophagy occurs only in the cytoplasm and 
in most of the cells it is on-going constitutively at 
a low activity. However, in stressful conditions it may 
be up-regulated to a high level, providing the cell 
with nutrients and energy substrates necessary to 
sustain basic cellular activities. To trigger the acute 
induction of autophagy signals about extracellular 
environmental conditions unfavourable for the cell 
(such as hypoxia or a lack of ATP, necessary nutrients 
or growth factors) and/or about disturbances in the 
intracellular environment (such as increased level 
of mis-/unfolded cytoplasmic proteins or unfolded 
protein response) are required.
Pathways of autophagy induction
The autophagy induction is characterized by fast 
kinetics due to post-translational modifications of 
many cellular components, including autophagy-rela-
ted proteins (Atg). The cascade of events linking the 
variety of autophagy-triggering signals with activation 
of downstream targets has not been completely eluci-
dated, however, two main pathways controlling auto-
phagy, mTOR-dependent and mTOR-independent, 
are currently being studied intensively [37]. The latter 
depends on mTOR-independent activators catego-
rised in different pharmacological classes including 
calpain inhibitors, type 1 imidazoline receptor (I1R) 
and voltage-gated sodium channel (Nav) agonists as 
well as voltage-gated potassium channel (Kv) and 
calcium channel (Cav) antagonists [37, 38].
The former canonical pathway depends on mam-
malian target of rapamycin (mTOR), Ser/Thr kinase 
being the main regulator of autophagy, indicated as 
a critical regulator of the balance between cell 
growth and autophagy in response to extracellular 
stresses and disturbances of intracellular physio-
logical conditions [39]. Within the eukaryotic cells 
mTOR is present in the form of at least two distinct 
multiprotein complexes of different intracellular 
activity and regulatory capacity. mTOR complex 
1 (mTORC1) is responsible for autophagy induc-
tion in response to stress, reduced IGF1/insulin 
signalling, and starvation [39, 40]. During such 
unfavourable conditions, mTORC1 dissociates 
from the Ulk1 complex (see below) allowing it to 
initiate autophagosome formation. In addition 
to mTOR, the other the main components of the 
mTORC1 comprise DEPTOR, raptor, GbL/mLst8, 
FKBP38 and PRAS40 proteins [41, 42]. mTOR 
complex 2 (mTORC2) is a negative regulator of 
autophagy under conditions of nutrient depletion 
[43]. In addition to the core compounds of the 
mTORC2 such as mTOR, ricor (rapamycin insen-
sitive companion of mTOR), Sin1/MIP and GbL/ 
/mLst8, there are also other non-canonical com-
ponents such as DEPTOR, protor/PRR5, Hsp70, 
Rac1, Tsc1/2 and Tel2/Tti proteins [44–47]. 
Autophagy signal transduction and corre-
sponding morphological changes
After activation by appropriate signalling pathways, au-
tophagy proceeds via a series of sequential stages that 
lead to the formation of several characteristic morpho-
logical structures (Figure 2.1) such as phagophore, au-
tophagosome, amphisome and autolysosome in which 
the targeted substrates become finally degraded by 
lysosomal hydrolases [37]. Phagophore formation and 
elongation are the first steps of autophagy. Recently, 
a double-layered isolation membrane, the omegasome 
structure localized in endoplasmic reticulum, has been 
proposed as an origin of the phagophore [48]. 
The process of formation of active phagophore 
(nucleation) requires the collective action of a few 
complexes (Figure 2.1): Atg1 complex, class III PI3K 
complex (including phosphatidyl inositol 3-phosphate 
kinase class III defined also as Vps34, core activator 
of the Vps34 PI3 kinase complex known as Vps15, 
enhancer of autophagosome formation Atg14 and 
Vps30/Atg6 orthologue Beclin1 the core subunits, 
bcl2-interacting protein), mAtg9/AtgL1 (Atg9 ortho-
logue in mammalian cells), Ambra 1 and UVRAG 
(Ultraviolet irradiation resistance-associated gene) 
which is a positive regulator of Vps34-Beclin1 com-
plex [49–56]. Many Atg’s have been identified in yeast. 
Although most of them are conserved in mammals, 
which is why information about orthologues is usually 
given, the molecular composition of the Atg1 complex 
differs between yeast and mammals. 
Mammalian autophagy factors of Atg1/Ulk1 com-
plex are Ulk1/2 (Unc51-like Ser/Thr kinases 1 and 2), 
255Role of proteasome inhibition in autophagy activation
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0036
www.fhc.viamedica.pl
Figure 2. Schematic presentation of molecular mechanisms linking proteasome inhibition to autophagy. Proteasome inhibition 
leads to the substantial changes in PI3K/Akt/mTOR signalling pathway, triggers unfolded protein response (UPR) and protein ag-
gregation/aggresomes formation. All those events occur during different stages of autophagy: formation of phagophore (Figure 2.1), 
autophagosome (Figure 2.2), amphisome (Figure 2.3) and, finally, autolysosome (Figure 2.4) where, having become damaged, 
the substrates are degraded by lysosomal hydrolases. Accumulation of the proteins LC3 and ATF4 due to the impairment of pro-
teasome function has been marked by a star. Detailed description of the processes has been provided in the main text
FIP200 which belongs to the focal adhesion kinase 
family interacting proteins, mammalian Atg13 and 
its binding protein, named Atg101 [55–57]. They are 
responsible for propagation of the signal initiating 
autophagy via phosphorylation of various substra-
tes. In physiological conditions (no cell starvation) 
mTORC1 suppresses the phagophore formation by 
direct interaction with the Ulk1 complex (Ulk1-At-
g13-FIP200-Atg101). The mTORC1 phosphorylates 
and inhibits Ulk1 and its interacting partner Atg13 
[58] as well as AMBRA1, the key link between 
Ulk1 and Beclin-1 complexes (for review see [54]). 
Moreover, mTORC1 controls WIPI2 (mammalian 
orthologue of Atg18), which is necessary for phago-
phore formation, and regulates DAP1, another potent 
autophagy inhibitor [48, 59]. During conditions of cell 
starvation mTORC1 releases Ulk1 complex, allowing 
it to associate with the membrane from which phago-
phore originates [50]. 
For the next stage, called expansion/sequestration, 
two ubiquitin-like conjugation systems are essential. 
The first one engages the formation of Atg5-12-16 
conjugate, mediated subsequently by E1- and E2-like 
enzymes, Atg7 and Atg10, respectively. The second 
system engages conjugation of microtubule-associated 
protein light chain 3 (LC3/Atg8) to the membrane 
phospholipid phosphatidylethanolamine (PE), the 
process also controlled by E1- and E2-like enzymes, 
Atg7 and Atg3, respectively. In human cells there 
are several cellular forms of LC3: full-length protein 
LC-3, the C-terminally cleaved protein referred to as 
LC3-I (LC3A) and the PE-conjugated form of LC3-I 
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referred to as LC3-II (LC3B) and LC3 paralog LC3C. 
During the expansion/sequestration stage, the phago-
phore enlarges, enwraps portions of cytoplasm with 
autophagic substrates and closes to form immature 
autophagosome (Figure 2.2). Once the autophagoso-
me is formed, Atg5-12-16 conjugate is detached and 
recycled. Also LC3-II from the outer autophagosome 
membrane is removed, while LC3-II that is attached 
to the inner membrane — remains [60]. The amount 
of LC3-II becomes a marker for the formation of au-
tophagosomes. The recent study performed on human 
cells infected with S. Typhimurium, showed that LC3C 
was required for antibacterial autophagy because in 
its absence the remaining ATG8 orthologs did not 
support efficient autophagy of intracellular bacteria 
[61]. The subsequent reports indicated that differen-
tial involvement of LC3 paralogs, LC3-II and LC3C, 
can classify autophagy in two separate programs that 
execute either pro- or anti-tumorigenic activities in 
renal cell carcinoma cells [62, 63].
Amphisome formation, fusion of autophagosome with 
endosome, the next stage of autophagy, is mediated 
by specific SNARE proteins and members of the Rab 
family (Figure 2.3). In this stage proteolytic enzymes 
from endocytic organelles with lowered pH to create 
an acidic milieu of an amphisome content. During the 
last stage of apoptosis (Figure 2.4), autolysosome forma-
tion, amphisome subsequently fuses with lysosome or 
late endosome to form an autolysosome in which the 
cytoplasmic cargo is degraded by lysosome hydrolases 
and degradation products are recycled for the synthesis 
of new molecules. The mechanisms of autophagosome 
maturation and subsequent fusion are complicated and 
have been recently reviewed [64, 65]; since published 
data do not link those processes directly with proteaso-
me inhibition, they will not be discussed in this review.
Crosstalk between proteasomal system  
degradation and autophagy pathways
Large protein aggregates, even ubiquitinated, are 
excluded from proteasomal degradation, and can be 
degraded only by autophagy. This process requires 
autophagosomal membrane receptors like multi-do-
main scaffold/adaptor protein p62/SQSTM-1, or 
a neighbour of BRCA1 gene 1 (NBR1) protein [66]. 
It has been reported that p62 binds non-covalently 
to the ubiquitin of polyubiquitinated proteins and 
then polymerises into cytosolic, nuclear and lysoso-
mal aggregates. p62 interacts with LC3 and acts as 
a bridge connecting ubiquitinated protein aggregates 
and autophagosomes [67]. Intriguingly, p62/SQSTM1 
is also known as an inhibitory factor of proteasomal 
degradation of LC3 [68]. 
In linking proteasomal degradation and autophagy 
an important role is also played by the tubulin deacety-
lase histone deacetylase 6 (HDAC6), the enzyme that 
regulates the acetylation of a-tubulin and facilitates 
transport of polyubiquitinated protein aggregates to 
the nascent phagophore (for review see [69]). HDAC6 
has been shown to be involved in both aggresome 
formation and the fusion of autophagosomes with 
lysosomes, making it an attractive target to regulate 
protein aggregation. Recent data shows direct inte-
raction between HDAC6 and p62; moreover, this in-
teraction regulates HDAC6 deacetylase activity [70].
New findings have documented the association 
between proteasomal degradation and autophagy 
pathways. It has been shown that pro- and anti-tumo-
rigenetic apoptotic programs are regulated by already 
mentioned constituent of UPS, von Hippel-Lindau 
tumour suppressor protein (VHL) which is E3 
ubiquitin ligase for hypoxia-inducible factor-1a (HI-
F-1a) [62, 63]. The VHL inhibits LC3-II-mediated 
autophagy and, in addition to the inhibition of HIF-1a 
protein, induces expression of the LC3C protein. 
Both VHL’s actions contribute to tumour-supressing 
autophagic activity. 
Proteasome inhibition is associated  
with autophagy
Proteasome inhibitors (see Table 1; data are based on 
[19, 20, 23, 28, 71–73]), including the multipathway 
inhibitor bortezomib, are drawing increased attention 
for their therapeutic potential in the treatment of 
chronic inflammation and cancer, especially tumo-
urs with a high degree of malignancy. Inhibition of 
proteasomal activities used to induce cell death has 
been previously shown to induce autophagy [74, 75] 
as well, indicating a coordinated and complementary 
relationships between these two protein-degradation 
systems.
Effects of different classes of proteasome 
inhibitors on autophagy in cancer
As explained earlier in this review, LC3-II and 
Beclin-1 proteins are necessary for autophagosome 
formation and, consequently, are commonly used 
as markers of autophagy. Increased cellular levels 
of LC3-II and Beclin-1 proteins were found after 
bortezomib treatment of human glioblastoma U251 
and U87 cells [74], melanoma cells [24], several cell 
lines of head and neck squamous cell carcinoma 
[76] and human osteosarcoma (HOS) cells [77]. 
In human colon cancer HCT116 cells and murine 
embryonic fibroblasts (MEFs) bortezomib increased 
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expression of LC3-II but did not lead to significant 
changes in Beclin-1 levels [75]. On the contrary, in 
the thyroid cancer cell line FRO82-1 bortezomib, 
as well as epoxomicin, increased the expression of 
LC3-II protein but reduced the protein level of Bec-
lin-1 [78]. Another proteasome inhibitor MG-132, 
in a time- and dose-dependent manner increased 
the content of LC3-II in HCT116 cells [75], colon 
cancer cells HT-29 [79, 80] and SW1116 [80], thyroid 
cancer cells [78], gastric cancer cells [81], HeLa cells 
[82], prostate cancer DU145 cells and MEFs [75] and 
in immortalized dopaminergic neuronal N27 cell 
line [83]. In the majority of the above-mentioned 
experimental conditions there were no significant 
changes in Beclin-1 levels, and in thyroid cancer cells 
a decrease of Beclin-1 protein level has been repor-
ted [78]. An increase of LC3 and LC3-II has been 
reported also after treatment with NPI-0052, ALLN 
(N-acetyl-leucyl-leucyl-norleucinal), epoxomicin 
and lactacystin of human prostate cancer cells [84], 
HCT116 cells [75], thyroid cancer cells [78], human 
dopaminergic neuroblastoma SH-SY5Y cells and 
dopaminergic neurons obtained from UPS-impaired 
mouse model of Parkinson’s disease (PD) [85, 86]. 
Differently than in the thyroid cancer cells [78], 
both in SH-SY5Y cells and in the midbrain of the 
UPS-impaired mouse model of PD, treatment with 
lactacystin significantly increased the level of not 
only LC3-I/II but also Beclin-1 protein, and reduced 
the levels of p-mTOR and mTOR [85]. Moreover, 
Marchantin M, a novel proteasome inhibitor te-
sted in prostate cancer cells, significantly induced 
expression of LC3-I and its further conversion to 
LC3-II [87]. 
Activation of autophagy measured by increased 
expression of LC3, LC3-II and Beclin-1 after the 
application of resveratrol was observed in a variety 
of cancer cell lines [32–34, 88]. Pterostilbene also 
caused a simultaneous increase in the expression of 
autophagic marker proteins Beclin-1 and/or LC3-II 
in breast [89, 90], lung [91] and bladder cancer cells 
[31] as well as in human leukaemia cells [92].
Direct effects of proteasome inhibition  
on autophagy markers
Autophagy is a dynamic process, and it is well known 
that LC3-II is degraded after fusion of autophagoso-
mes with lysosomes [56, 93]. It was shown that the 
processing of LC3 occurs via the 20S proteasome. 
This processing is ubiquitin- and ATP-independent, 
and both the N-terminal helices and the ubiquitin 
fold of LC3 are required. The addition of the N-ter-
minal helices of LC3 to the N-terminus of ubiquitin 
renders ubiquitin susceptible to 20S proteasomal 
activity. Furthermore, the 20S proteasome processes 
LC3 in a few stages. Initially, it cleaves LC3 within its 
ubiquitin fold, and this leads to the disruption of the 
conjugation function of LC3. Finally, in the presence 
of high amount of active proteasomes, LC3 becomes 
completely degraded [68]. Therefore, inhibition of 
proteasome activity may lead to the accumulation of 
LC3-II proteins (Figure 2). Also, inhibition of auto-
phagic degradation can often lead to the accumulation 
of LC3-II proteins [94]; however, in all the above-cited 
papers rapidly activated autophagy after proteasome 
inhibition was observed [75, 85]. The presence of 
a considerably increased number of autophagosomes 
at various stages was postulated as the most convin-
cing proof of active ongoing autophagy after prote-
asome inhibition by different groups of proteasome 
inhibitors [24, 88, 91, 95–97].
A study performed on HCT 116 cells showed that 
proteasome inhibitors (MG-132, lactacystin, ALLN 
and bortezomib) did not affect the expression level of 
other proteins important for the autophagy stage of 
expansion/sequestration, namely Atg5 and Atg7 [75]. 
On the contrary, in other experimental model, some 
lines of human prostate cancer cells (LNCaP-Pro5) 
treated with bortezomib and NPI-0052 showed an 
increase in Atg5 and Atg7 transcription [84], also tre-
atment with resveratrol increased the level of Atg5 in 
glioma cells [88].
The influence of proteasome inhibition on auto-
phagy at the stages of amphisome and autolysosome 
formation has not been yet extensively investigated. 
Experiments on HCT 116 cells revealed that the 
co-localization of GFP-LC3 (an autophagosome 
marker) with Lamp-1 (a lysosome marker) after 
incubation with MG132, the covalent proteasome 
inhibitor, was similar to the co-localization of this 
proteins in untreated control cells. Moreover, it 
was reported that MG132 did not affect the fusion 
of autophagosomes with lysosomes [98]. According 
to another report, treatment with resveratrol, also 
a covalent proteasome inhibitor, leads to blockade of 
autolysosome formation, as assessed by the absence 
of co-localization of LC3 and Lamp-2 [99]. Experi-
mental studies designed to evaluate if non-covalent 
proteasome inhibitor Marchantin M has an influence 
on the fusion process of amphisome and lysosomes, 
did not show any blockade of autolysosome formation 
[87]. The main conclusion from those reports is that 
the effects of proteasome inhibition on mechanisms 
of autophagosome maturation and fusion are ambi-
guous, which probably results from the great variety 
of chemical structures and activities of various pro-
teasome inhibitors. 
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The main pathways of autophagy activation 
in response to UPS inhibition
Unfolded Protein Response
To date, several different pathways which explain 
the activation of autophagy after proteasome inhi-
bition have been described. The best documented 
is the pathway linking autophagy activation with the 
response to endoplasmic reticulum (ER) stress — 
disruption of endoplasmic reticulum homeostasis 
caused by accumulation of misfolded proteins not 
processed by functionally impaired proteasomes [75]. 
The unfolded protein response (UPR), also called 
protective hypoxia-inducible factor (HIF)-indepen-
dent pathway [100], is considered to be the major com-
pensatory and protective mechanism during ER stress. 
Among the three known pathways of UPR mediated 
by (i) ER-resident protein kinase/eukaryotic initiation 
factor 2 (PERK/eIF2a), (ii) activating transcription 
factor 6 (ATF6), and (iii) inositol-requiring kinase 
(IRE1), the last one was initially proposed as the most 
important in proteasome-induced autophagy. IRE1 is 
responsible for the activation of two well-established 
mechanisms in mammalian cells. The first one, activa-
tion of c-Jun NH2-terminal kinase (JNK), is required 
for the processes leading to cell death by apoptosis 
[101, 102]. The second mechanism involves an alter-
native splicing of a XBP-1 gene transcript, leading to 
the formation of an active transcription factor that 
participates in UPR [103, 104]. According to Ding et 
al. [75], JNK but not XBP-1 seems to be involved in 
the induction of autophagy after treatment with prote-
asome inhibitors. In a subsequent study these authors 
observed that increased autophagy in HOS cells in 
response to bortezomib corresponded with altered 
levels of intracellular mitogen-activated protein ki-
nase (MAPK) signalling molecules such as decreased 
levels of phosphorylated MAPK kinase (MEK1/2) and 
extracellular signal-regulated kinase (ERK1/2), and 
simultaneous increase of phosphorylated JNK and 
p38 MAPK [77]. Also, after exposure of melanoma 
cells to bortezomib, no changes were observed in 
the total expression levels of IRE1, ASK1, JNK and 
p38, however, this proteasome inhibitor triggered 
the phosphorylation of these proteins [24]. The link 
between JNK1 activation via IRE-1-mediated UPR 
and autophagy induction by proteasome inhibition can 
be explained in the following way. Active, phospho-
rylated JNK1 mediates Bcl-2 phosphorylation, Bcl-2 
dissociation from Beclin-1 and consequently activates 
autophagy [105]. A similar effect, however, with the 
involvement of MCL-1 protein, can be mediated by 
active p38, another downstream substrate of IRE-1. 
Results of several reports showing that proteasome 
inhibition leads to the induction of the phosphoryla-
tion of anti-apoptotic proteins such as Bcl2, Bcl-xL 
or MCL-1, and autophagy [24, 76, 106, 107] support 
the theory that both signal transduction pathways, 
i.e. JNK1/Bcl-2 and p38/MCL-1 become activated by 
proteasome inhibitors. 
Many studies showed that PERK/eIF2a canonical 
signalling pathway, which mediates autophagy during 
ER stress, may be triggered by proteasome inhibition 
[87, 108–110]. Studies on Marchantin M-induced, 
PI3K/Vps34-dependent autophagy revealed that not 
the IRE1/JNK pathway but the PERK/eIF2a pathway 
seemed to be involved in autophagy induction by this 
proteasome inhibitor [87]. Although activation of 
the IRE1-mediated pathway of UPR was observed, 
a downstream effect of this activation was the incre-
ase in the spliced form of XBP-1 mRNA, however, 
the translated protein was found to be not involved 
in the autophagy induction [87]. In the same study, 
evaluation of ATF6-mediated pathway showed just 
a slight increase of ATF6 mRNA.
Activation of the PERK/eIF2a pathway and pho-
sphorylation of eIF2a by PERK leads to general in-
hibition of protein synthesis, but also selectively pro-
motes translation of some proteins, including ATF4 
(Activating Transcription Factor 4) (Figure 2). 
It is in accordance with growing evidence that the 
transcription factor ATF4 is an important player 
in proteasome inhibitor-induced autophagy. ATF4 
binds to the LC3 promoter under basal and hypoxic 
conditions to up-regulate the LC3 cellular expres-
sion [111] and, in this way, to promote autophagy. 
The subsequent increases in the transcription of the 
ATG5 and ATG7 genes in response to the increased 
ATF4 levels are related to the fact that the promo-
ter regions of ATG5/7 contain ATF/CREB binding 
sites [84, 111]. 
Many data suggest that proteasome inhibitors 
may significantly increase ATF4 gene expression. 
After incubation of two human liver tumour cell lines 
(HepG2 and HA22t/VGH) with MG-132 the level of 
ATF4 mRNA was enhanced in both cell lines [112]. 
Bortezomib also caused increased gene expression 
of ATF4 gene in various cell lines of human multiple 
myeloma [113] and rats liver cells [114]. In human 
LNCaP-Pro5, PC3 and PC3-R prostate cancer cell 
lines and MEFs treated with bortezomib and NPI-
0052 [84], the eIF2a phosphorylation-dependent 
mechanism was at least partially responsible for the 
increase in ATF4 level after proteasome inhibition. 
Interestingly, also resveratrol significantly increased 
ATF4 gene expression in HEK293 cells [115].
It has to be mentioned that the increased level 
of ATF4 protein observed after proteasome inhi-
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bition [116, 117] may be not only the result of the 
downstream activity of PERK, but could be also a 
consequence of the inhibition of its degradation by 
proteasomes and accumulation within cell (Figure 
2). It was reported that bTrCP1, a ligand-binding 
subunit of SCF/b-TrCP E3 ubiquitin ligase complex, 
decreased ATF4 protein level by ubiquitination which 
lead to its proteasomal degradation [118]. The study 
of human breast cancer cell lines MCF7 and MDA 
MB 231 showed that, independently of the upstream 
activity of PERK, after treatment with bortezomib 
ATF4 was protected against proteosomal degradation 
and directly stabilized. These processes resulted in an 
increase of LC3B cellular level [117]. 
PI3K/Akt/mTOR
There is a convincing evidence that the PI3K/Akt/ 
/mTOR pathway represents the major regulatory me-
chanism of autophagy. Activity of mTOR is primarily 
maintained by an active PI3K/Akt kinase pathway, 
while the AMP-activated protein kinase a1 subunit 
(AMPKa1) acts as the main inhibitor of mTOR acti-
vity [119]. Activated mTOR in mTORC1, in addition 
to inhibition of the membrane targeting of the Ulk1 
complex by direct interaction with it, phosphorylates 
eukaryotic initiation factor 4E-binding protein 1 
(4E-BP1) and p70S6 kinase (p70S6K) to increase 
cap-dependent translation and translation initiation 
complex formation, respectively [120]. Inhibited 
mTORC1 disinhibits kinase Ulk1/2 activities, resul-
ting in FIP200 phosphorylation, which is required for 
the early stages of autophagosome formation [50]. 
It has been reported that after MG-132 application 
in various experimental cell culture models [79–81, 
121] characteristic features of increased autophagy 
were accompanied by pronounced inhibition of 
mTORC1-mediated phosphorylation of 4E-BP1 and 
S6K. Initially, the mechanism by which proteasome 
inhibition resulted in the disruption of mTORC1 
remained vague, but recent studies using bortezomib 
as an autophagy inducer showing up-regulation of 
sestrin-2 (SESN2/Hi95) [122] have shed new light on 
this problem. SESN2 protects cells against oxidative 
and genotoxic stresses, and mediates the inhibition of 
mTOR [123]. Thus, the bortezomib-induced increase 
of SESN2 level leads to the inhibition of the main 
regulatory subunits of mTORC1 by a mechanism 
that requires interaction with AMPKa1 to mediate 
the phosphorylation of tuberous sclerosis2 (TSC2), 
an upstream mTOR inhibitor [119]. 
Moreover, it should be pointed out that SESN2 
is a product of the p53 target gene [124]. Significant 
increase of p53 level in several cancer cell lines has 
been reported after bortezomib administration [125] 
and in dopaminergic neurons after lactacystin admi-
nistration [126]. Lactacystin treatment resulted in the 
induction of autophagy mediated by p53 but not by 
the UPR. Several pathways through which increases 
in p53 are able to up-regulate autophagy in non-
cancerous cells have been discussed. Among them, 
activation of AMPKa1 and subsequent inhibition of 
mTOR have been proposed so far, but involvement 
of SESN2 also has to be taken into consideration 
[49, 124]. However, most cancer cells lack functional 
p53, indicating induction of ATF4-mediated [122] or 
the recently described pJNK-mediated [127] SESN2 
expression as an essential factor linking ER stress 
or proteasome inhibition to mTOR inhibition and 
autophagy in cancer cells.
The above-mentioned mechanism of AMPKa1 
activation, which in turn inhibits mTOR, was also 
described after incubation of human umbilical vein 
endothelial cells (HUVECs) with pterostilbene, 
a naturally occurring polyphenol. Pterostilbene pro-
moted autophagy via a rapid elevation of intracellular 
calcium concentration and subsequent activation of 
AMPKa1 [128]. Another form of autophagy induction 
was observed after cells’ treatment with Marchantin 
M. This proteasome inhibitor decreased mTOR 
protein levels [85] or inhibited mTOR activators 
pospho-Akt and 3-phosphoinositide-dependent 
protein kinase-1 (PDK1) [87]. Pterostilbene-induced 
autophagy in human lung cancer cell lines, confirmed 
by the formation of acidic vesicular organelles and LC-
3-II production, was also mediated by the inhibition of 
PI3K/Akt [91]. Under these experimental conditions, 
as well as in resveratrol-induced autophagy in hu-
man U373 glioma cells, activation of the Ras/Raf-1/ 
/mitogen-activated protein kinase 1/2 (MEK1/2)/ 
/extracellular signal-regulated kinase 1/2 (ERK1/2) 
pathway has been observed [34]. However, data are 
still scarce, and the mechanisms linking this pathway 
with autophagy induced by proteasomal inhibition 
need further clarification.
Formation of aggresomes
Proteasome inhibition leads to the accumulation of 
protein, often polyubiquitinated, which are prone to 
aggregate and make structures known as ‘aggresomes’. 
Aggresomes are predominantly present in perinuclear 
compartments, and they are considered to be a place 
of selective autophagy of damaged proteins that are 
isolated from other cytoplasmic components [129]. 
The clearance of polyubiquitinated proteins present in 
aggresome is mediated by ubiquitin-binding proteins 
like p62/SQSTM1 (Figure 2). p62/SQSTM1 seems 
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to be a connecting link between autophagy and pro-
teasome-mediated proteolysis, and its level strongly 
increases during exposure to various oxidative agents 
and proteasomal inhibitors, such as MG-132, lactacy-
stin, epoxomicin and PSI [66, 130–132]. Furthermore, 
proteasomal inhibition caused by MG-132 leads to 
accumulation of p62/SQSTM1 bound irreversibly to 
perinuclear protein aggregates [132]. This phenome-
non may be explained, at least partially, on the basis 
of experiments performed with MG-132 in the ARPE-
19 cell line [132]. Viiri et al. studied the involvement 
of ELAVL1/HuR protein in the regulation of p62/ 
/SQSTM1 synthesis. ELAVL1/HuR is a post-tran-
scriptional factor, which acts mainly as a positive 
regulator of gene expression by binding to specific 
mRNAs, which corresponding proteins play a key 
role in cell functions. During proteasomal inhibition 
ELAVL1/HuR was up-regulated at both mRNA 
and protein levels, and was shown to bind with and 
post-transcriptionally regulate p62/SQSTM1 mRNA 
[132]. On the other hand, substantial decreases in 
p62/SQSTM1 levels after proteasomal inhibition in 
human osteosarcoma (HOS) cells have been reported 
[77]. Also, after treatment of human dopaminergic 
neuroblastoma SH-SY5Y cells with the proteasome 
inhibitor lactacystin, and in dopaminergic neurons 
obtained from a UPS-impaired mouse model of Par-
kinson’s disease, significantly reduced levels of p62/ 
/SQSTM1 were found [85]. In accordance with those 
data, time kinetic studies revealed that Marchantin 
M decreased the expression of p62/SQSTM1 [87]. 
Interestingly, p62/SQSTM1 is itself an autophagy 
substrate, responsible both for the transport of poly-
ubiquitinated protein aggregates to autophagosomes, 
and the promotion of their uptake to the lysosomes. It 
has been proposed that p62, even when up-regulated, 
is intensively degraded during process of autophagy 
and autophagy up-regulation causes a reduction of 
p62 levels [130, 133]. 
HDAC6 is thought to be a sensor of proteasomal 
inhibition and a cellular stress surveillance factor 
playing a key role in autophagy by controlling the 
fusion process of autophagosomes with lysosomes 
(for review see [69, 100]). UPS inhibition leads to 
HDAC6 relocation and inclusion into aggresomes 
[134, 135]. Because HDAC6 is involved in both ag-
gresome formation and the fusion of autophagosomes 
with lysosomes, HDAC6 inhibition can enhance 
the cytotoxicity of proteasome inhibitors [117]. The 
role of HDAC6 during the proteasome inhibition 
seems to be unrelated with its signalling to increase 
autophagic flux, but rather with efficient delivery of 
accumulated polyubiquitinated substrates for degra-
dation (reviewed in [69]). In addition, HDAC6 may 
control another mechanism to facilitate cell survival, 
despite the inhibition of proteasome activity. Kästle 
et al. [136] found that after proteasome inhibition 
caused by lactacystin administration, the up-regula-
tion of heat shock protein heme oxygenase-1 (HO-1) 
was controlled by HDAC6. They showed that under 
these experimental conditions, HDAC6 deacetylates 
p38, allowing subsequent phosphorylation of p38 and 
resultant activation of NRF-2, a transcription factor 
for HO-1 [136]. These results complement previous 
reports which showed that the induction of classical 
heat shock proteins, e.g. Hsp27 and Hsp70, required 
activation of HDAC6 which triggered the dissociation 
of HSF1 (heat-shock factor 1) from HDAC6/HSF1/ 
/HSP90 complex and a subsequent HSF1 activation 
[137, 138]. In turn, activation of HSF1 induces the 
expression of newly synthesized heat shock proteins, 
which are necessary to prevent cellular damage caused 
by proteasome inhibition. 
Recent studies indicate that BAG3 (Bcl-2 associa-
ted athanogene 3), which was previously linked with 
various physiological and pathological processes, inc-
luding signal transduction and apoptosis [139], has 
been recently associated with autophagy (Figure 2), 
mainly of misfolded non-polyubiquitinated proteins 
found in aggresomes [140, 141]. BAG3 belongs to the 
BAG co-chaperone family responsible for the regula-
tion of the ATPase activity of the heat shock protein 
70 chaperone family. A study utilizing MG-132 pro-
teasome inhibitor showed that BAG3 interacted with 
Hsp70 to facilitate and selectively direct substrates to 
the aggresomes; additionally, this mechanism did not 
depend on substrate ubiquitination [140]. Treatment 
of rhabdomyosarcoma cells with bortezomib and 
ST80 (cytoplasmic histone deacetylase 6 inhibitor) 
up-regulated BAG3 at both mRNA and protein 
levels in surviving cells as well as triggered the accu-
mulation of insoluble protein aggregates [142]. These 
results allowed putting forward the thesis, that BAG3 
may be a novel mediator of inducible resistance to 
proteasome inhibition by mitigating proteotoxicity 
via induction of autophagy. BAG3 was also shown 
to be involved in proteasome inhibitor-elicited non-
canonical autophagy in hepatocellular carcinoma 
cells, which was not suppressed by inhibitors of class 
III PI3K or shRNA against Beclin-1 mRNA [143]. 
Final remarks
Recent experimental and clinical data have shown that 
proteasome inhibitors serve as a new and promising 
class of anticancer agents [21, 24, 77, 79, 84, 87, 144]. 
However, the data presented in this review proved 
beyond doubt that proteasome inhibition induces 
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autophagy in the majority of cells. The described 
complex network of processes leading to the activation 
of autophagy (Figure 2), despite being more precise 
than presented in reviews based on data available only 
a year ago, seem to be only a mere outline of compli-
cated crosstalks between UPS and autophagy. It turns 
out that the two systems of protein degradation which 
were originally regarded as rather independent may be 
very closely related. According to majority of experi-
mental data the over-activation of autophagy induces 
cell death and acts as a powerful tumour-supressing 
mechanism [35]. However, the autophagy, serving 
as an important mechanism to generate nutrients in 
time of cellular stresses, may directly contribute to the 
survival of cells treated with proteasome inhibitors, 
and consequently, may decrease the effectiveness 
of anti-cancer therapy [117]. Preclinical studies per-
formed on several cancer cell types [75, 117] have 
already shown synergy between simultaneously used 
proteasome and autophagy inhibitors. 
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